Clinical Study of MNC-168 Enteric-coated Capsule in the Treatment of Advanced Intestinal Solid Tumor
Status:
Not yet recruiting
Trial end date:
2024-04-10
Target enrollment:
Participant gender:
Summary
This study is a multicenter, open-label, dose-escalation Phase I clinical trial designed to
evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy
of live bacterium MNC-168 as a single oral agent in subjects with advanced malignant solid
tumors. To explore the changes of biomarkers and intestinal flora related to curative effect,
mechanism of action, safety and/or pathological mechanism.